Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin
- 47 Downloads
This study was designed to evaluate the association of non-genetic factors and polymorphisms CYP2C9*2 (rs1799853), CYP2C9*3 (rs1075910), and VKORC1-G1639A (rs9923231) with time in therapeutic range (TTR), and to build a regression model to predict the quality of oral anticoagulation control in a sample of Brazilian patients.
This is a retrospective cohort study developed at an anticoagulation clinic of a university hospital. Overall, 312 patients were included. The quality of oral anticoagulation control was evaluated by TTR. TTR was dichotomized for analysis, using two cutoff points for classification as inadequate (TTR ≤ 60.0%) and optimal (TTR ≥ 75.0%) control.
The average age was 60.4 ± 13.5 years, with a predominance of women (187; 59.9%). The -G1639A polymorphism of the VKORC1 gene, when evaluated, based on the recessive inheritance pattern [AA × (GA + GG)], patients with AA genotype exhibited a higher TTR (68.2% versus 62.8%, p = 0.017). TTR ≤ 60.0% was associated with number of drugs in chronic use, assistance for warfarin administration, reports of not taking warfarin, absenteeism, sex (female), and target INR (International Normalized Ratio; 2.00–3.00). TTR ≥ 75.0% was associated with sex (male), target INR (2.00–3.00), assistance for warfarin administration, reports of not taking warfarin, and absenteeism. The two algorithms proposed showed adequate ability to predict TTR presenting good sensitivity and specificity.
Our findings provided useful information for risk stratification depending on TTR level and for future investigations on the quality of oral anticoagulation control in Brazilian anticoagulation clinics.
KeywordsAlgorithms Warfarin Cytochrome P-450 CYP2C9 VKORC1 protein Quality of health care
MFSP analyzed the database, interpreted the results obtained, and drafted the manuscript following the suggested recommendations from other authors. MOCR and MAPM contributed significantly to the conception and design of the study, reviewed the study proposal, and participated in drafting the manuscript and in each subsequent revision. AOMM designed the study, organized data collection, analyzed the data, interpreted the results, and revised the manuscript. KBGG and EIFC contributed to the process of genotyping and revised the manuscript critically. EAR provided statistical support and revised the manuscript. RPS provided statistical support, analyzed the data, organized data collection, interpreted the results, and revised the manuscript. DDR critically reviewed the manuscript.
This study was supported by the National Council for Scientific and Technological Development (CNPq), the Coordination for the Improvement of Higher Level Education Personnel (CAPES) and the State of Minas Gerais Research Foundation (FAPEMIG), Brazil, and the Pró-reitoria Pesquisa of the Universidade Federal Minas Gerais, Brazil. KBG, RPS, and MOCR are fellows of CNPq.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e44S–e88S. https://doi.org/10.1378/chest.11-2292 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Connolly SJ, Pogue J, Eikelboom J et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037. https://doi.org/10.1161/CIRCULATIONAHA.107.750000 CrossRefPubMedGoogle Scholar
- 7.White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239–245. https://doi.org/10.1001/archinte.167.3.239 CrossRefPubMedGoogle Scholar
- 9.Costa GL, Lamego RM, Colosimo EA et al (2012) Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther 34:1511–1520. https://doi.org/10.1016/j.clinthera.2012.06.002 CrossRefPubMedGoogle Scholar
- 11.Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee A, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M, EU-PACT Group (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369:2294–2303. https://doi.org/10.1056/NEJMoa1311386 CrossRefPubMedGoogle Scholar
- 13.Wen MS, Chang KC, Lee TH, Chen YF, Hung KC, Chang YJ, Liou CW, Chen JJ, Chang CH, Wang CY, Jeng JS, Chuang HP, Chen YT, Chen CH, Wu JY, Chen YT, Lee MT (2017) Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial. Pharmacogenomics 18:245–253. https://doi.org/10.2217/pgs-2016-0154 CrossRefPubMedGoogle Scholar
- 22.Santos PC, Marcatto LR, Duarte NE et al (2015) Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics 16:865–876. https://doi.org/10.2217/pgs.15.48 CrossRefPubMedGoogle Scholar
- 23.Park YK, Lee MJ, Kim JH, Lee JS, Park RW, Kim GM, Chung CS, Lee KH, Kim JS, Lee SY, Bang OY (2017) Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation. J Stroke Cerebrovasc Dis 26:1383–1390. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.02.022 CrossRefPubMedGoogle Scholar
- 24.Friedrich DC, Genro JP, Sortica VA, Suarez-Kurtz G, de Moraes ME, Pena SD, dos Santos A, Romano-Silva MA, Hutz MH (2014) Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One 9:e110691. https://doi.org/10.1371/journal.pone.0110691 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. https://doi.org/10.1111/jth.13140 CrossRefGoogle Scholar
- 29.Redman AR, Zheng J, Shamsi SA, Huo J, Kelly EJ, Ho RJ, Ritchie DM, Hon YY (2008) Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy. Clin Appl Thromb Hemost 14:29–37. https://doi.org/10.1177/1076029607304403 CrossRefPubMedGoogle Scholar
- 34.Yao X, Abraham NS, Alexander GC et al (2016) Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 5. https://doi.org/10.1161/JAHA.115.003074
- 38.Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, Kaatz S, Eikelboom JW (2010) Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 8:101–106. https://doi.org/10.1111/j.1538-7836.2009.03652.x CrossRefPubMedGoogle Scholar
- 39.Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH (2011) Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 72:442–450. https://doi.org/10.1111/j.1365-2125.2011.03942.x CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Soares RA, Santos PC, Machado-Coelho GL, do Nascimento RM, Mill JG, Krieger JE, Pereira AC (2012) CYP2C9 and VKORC1 polymorphisms are differently distributed in the Brazilian population according to self-declared ethnicity or genetic ancestry. Genet Test Mol Biomarkers 16:957–963. https://doi.org/10.1089/gtmb.2012.0019 CrossRefPubMedGoogle Scholar
- 41.Santos PC, Dinardo CL, Schettert IT, Soares RA, Kawabata-Yoshihara L, Bensenor IM, Krieger JE, Lotufo PA, Pereira AC (2013) CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol 69:789–797. https://doi.org/10.1007/s00228-012-1404-5 CrossRefPubMedGoogle Scholar
- 42.de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL (2014) Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with twith thrombosis: a prospective cohort study. Mol Diagn Ther 18:675–683. https://doi.org/10.1007/s40291-014-0121-4 CrossRefPubMedGoogle Scholar
- 45.Heneghan C, Ward A, Perera R, Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Körtke H, Levi M, Matchar D, Menéndez-Jándula B, Rakovac I, Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K, Shalansky K, Völler H, Wagner O, Zittermann A (2012) Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379:322–334. https://doi.org/10.1016/S0140-6736(11)61294-4 CrossRefPubMedGoogle Scholar
- 47.Connock M, Stevens C, Fry-Smith A et al (2007) Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 11(3–4):9–66Google Scholar
- 48.Ontario HQ (2009) Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ont Heal Technol Assess Ser 9:1–114Google Scholar